BugSeq Bioinformatics
BugSeq Bioinformatics is a cloud-based automated bioinformatics platform that processes raw sequencing data from Illumina, Nanopore, and PacBio instruments for clinical microbiology, public health, and defense laboratories, delivering pathogen identification and antimicrobial resistance prediction within hours.
- Company typePrivate
- Founded2020
- HeadquartersVancouver, Canada
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What BugSeq Bioinformatics does
BugSeq Bioinformatics Inc. is a Vancouver-based, US-incorporated cloud bioinformatics company founded in 2020 that operates a fully automated platform for clinical and public health microbiology laboratories. The platform ingests raw sequencing data from Illumina, Nanopore, and PacBio instruments and produces taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification reports within hours, eliminating the need for in-house bioinformatics infrastructure. The company's core technical differentiator is its curated reference database, which reports less than 0.0001% taxonomic misannotation and sequence contamination versus standard RefSeq-based pipelines, and its pathogen-specific pipeline library covering more than 20,000 bacteria, 10,000 viruses, 20,000 fungi, and 1,000 parasites.
The product portfolio consists of a single BugSeq Platform with eight integrated analysis modules, four clinical applications (clinical metagenomics, hospital-acquired infections, 16S/ITS, viral analysis), and pathogen-specific pipelines organized by organism kingdom. BugSeq distributes via a hybrid product-led and enterprise sales motion: a free 10-sample self-serve trial converts users into one of three annual subscription tiers (Core up to 1,000 samples/year, Advanced up to 3,000 with SSO and validation tooling, and Premier up to 7,000 with API integration for regulated diagnostics), while enterprise field sales target clinical labs, public health agencies, and defense organizations through quote-based pricing. The company reports being trusted by hundreds of labs and supports multiple peer-reviewed publications validating its accuracy.
Revenue mechanics are SaaS subscription-based with annual billing, supplemented by consortium and grant funding. BugSeq joined the RANGER consortium in February 2025 (led by Ginkgo Bioworks with Jumpcode Genomics, Planet Innovation, TGen, and funded by the European Commission's HERA budget) to develop an end-to-end rapid metagenomic diagnostic device eligible for up to €24 million over four years, with clinical validation at UZ Leuven, Karolinska University Hospital, and Tartu University Hospital as part of a path to EU IVDR certification. CEO Sam Chorlton leads the company, which currently operates with 1-10 employees.
BugSeq Bioinformatics firmographics
Firmographics- Name
- BugSeq Bioinformatics
- Legal name
- BugSeq Bioinformatics Inc.
- Website
- https://bugseq.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- BugSeq Bioinformatics is a cloud-based automated bioinformatics platform that processes raw sequencing data from Illumina, Nanopore, and PacBio instruments for clinical microbiology, public health, and defense laboratories, delivering pathogen identification and antimicrobial resistance prediction within hours.
- Ownership category
- akta.pro rank
Where BugSeq Bioinformatics is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Markets served
BugSeq Bioinformatics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Subscription-based SaaS Platform: BugSeq operates on a subscription SaaS model with tiered pricing (Core, Advanced, Premier) based on sample volume and feature access. Pricing scales with annual sample volume from 1000 samples/year (Core) to 7000 samples/year (Premier), with additional features like data retention, SSO, pipeline versioning, and API integration at higher tiers.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Core plan - Foundational tools for high-impact research and pilot studies |
| Subscription | Annual | Advanced plan - Routine volume, collaboration and compliance |
| Subscription | Annual | Premier plan - Gold standard for regulated molecular diagnostics and IVD |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
BugSeq Bioinformatics product offering
Product offeringCore offering
BugSeq operates a fully automated, cloud-based bioinformatics platform for microbiology labs that ingests raw sequencing data from Illumina, Nanopore, and PacBio instruments and produces actionable taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification reports within hours, without requiring dedicated bioinformatics infrastructure. It is sold as a tiered annual SaaS subscription (Core, Advanced, Premier) scaled by annual sample volume and regulatory feature requirements.
Product overview
BugSeq is a fully automated cloud-based bioinformatics platform offering end-to-end pathogen analysis for microbiology labs. The platform processes raw sequencing data from Illumina, Nanopore, and PacBio instruments, providing taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification. The product portfolio consists of a core platform with multiple integrated analysis modules (Taxonomic Classification, Antimicrobial Resistance Analysis, Outbreak Analysis, Plasmid Detection, Quality Control, Subtyping, Pathogen Identification, and Curated Database), pathogen-specific pipelines for bacteria (20,000+), viruses (10,000+), fungi (20,000+), and parasites (1,000+), and four clinical applications (Clinical Metagenomics, Hospital Acquired Infections, 16S/ITS Analysis, and Viral Analysis). Pricing is offered in three tiers: Core (up to 1000 samples/year), Advanced (up to 3000 samples/year with SSO and validation tooling), and Premier (up to 7000 samples/year with API integration for regulated diagnostics/IVD).
Differentiator
Problem solved
Functional benefit
Products and services
- BugSeq Platform
Quantifiable outcome
- Taxonomic misannotation reduced to <0.0001% vs 1% in RefSeq
- +3 more outcomes
Companies that use BugSeq Bioinformatics
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
BugSeq Bioinformatics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature9 records
BugSeq Bioinformatics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Ginkgo BioworkscoreBugSeq participates in the RANGER (RApid Next Generation Sequencing for Effective Medical Response) consortium led by Ginkgo Bioworks to develop a rapid, metagenomic next-generation sequencing (mNGS) solution enabling same-day diagnostics for respiratory viruses in hospitals. Consortium partners eligible for up to €24 million in funding over four years through European Commission HERA budget.
- Jumpcode GenomicscoreJumpcode Genomics is a consortium partner in the RANGER project providing CRISPR-based technology for the Cipher system. Their expertise complements BugSeq's bioinformatics platform in the integrated diagnostic solution.
- Planet InnovationcorePlanet Innovation leverages its product development and manufacturing capabilities to develop the Cipher benchtop system. Their expertise in world-class platform development complements BugSeq's bioinformatics analysis capabilities.
- TGen (Translational Genomics Research Institute)coreTGen is a consortium partner contributing to clinical validation of the rapid metagenomic diagnostic solution developed through the RANGER project.
- Oxford Nanopore TechnologiescoreBugSeq partners with Oxford Nanopore for joint webinars on real-time infectious disease outbreak investigations using nanopore sequencing and BugSeq analysis. BugSeq's platform is optimized for Nanopore long-read sequencing data.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
BugSeq Bioinformatics competitors and assessment
Company assessmentEmerging players
- Chan Zuckerberg Biohub (IDseq): Open-source metagenomics analysis platform developed at the Chan Zuckerberg Biohub for pathogen detection from sequencing data. Comparable in core functionality (taxonomic classification, AMR, outbreak tracking) and partially in target users (public health and research labs), but offered free versus BugSeq's subscription model.
Broad incumbents
- bioMérieux: Global leader in in vitro diagnostics for clinical microbiology, including molecular diagnostics and antimicrobial susceptibility testing. Comparable as a broader incumbent whose installed base in clinical microbiology labs is the customer ecosystem BugSeq is targeting with sequencing-based analysis.
- Illumina: Dominant sequencing vendor offering DRAGEN bioinformatics for secondary and tertiary analysis of sequencing data, including metagenomics. Comparable as the most entrenched incumbent that bundles analytics with its instruments and competes for the same clinical microbiology and public health budgets.
- QIAGEN: Broad life sciences tools company with CLC Genomics Workbench and QIAseq bioinformatics solutions used in microbial genomics and clinical research. Comparable because it offers an established, regulated bioinformatics platform that competes for the same clinical and public health laboratory customers.
Others
- Ginkgo Bioworks: Synthetic biology platform and R&D services company that leads the RANGER consortium in which BugSeq participates. Comparable because Ginkgo is both a partner and adjacent competitor with growing capabilities in pathogen genomics, biosecurity and large-scale metagenomic programs.
- DNAnexus: Cloud genomics data platform offering infrastructure, pipelines and analysis environments for sequencing data. Comparable as enabling infrastructure that competes for clinical bioinformatics workloads and could host alternative metagenomics pipelines to BugSeq.
Direct peers
- One Codex: Cloud-based microbial genomics platform offering taxonomic classification and AMR analysis for sequencing data. Directly comparable as a SaaS bioinformatics platform focused on microbial identification and AMR, serving both clinical and food/agriculture testing labs.
- Karius: Clinical infectious disease diagnostics company using sequencing (cell-free DNA) to identify pathogens from blood samples. Comparable as a clinical metagenomics player pursuing hospital adoption of sequencing-based pathogen detection, with overlapping regulatory and clinical validation challenges.
- CosmosID: Commercial microbial identification and AMR platform built on curated databases and metagenomic analysis. Directly comparable in target customers (clinical and food safety labs), core function (pathogen ID + AMR) and business model (subscription bioinformatics for sequencing data).
- Oxford Nanopore Technologies: Sequencing platform vendor with EPI2ME, its native bioinformatics suite for metagenomic and pathogen analysis on Nanopore data. Highly comparable because BugSeq's platform is optimized for and partnered with Nanopore, and EPI2ME represents the most direct competitive alternative for Nanopore customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
BugSeq Bioinformatics social profiles
Digital presenceBugSeq Bioinformatics compliance and trust
Trust signalCompliance2 records
BugSeq Bioinformatics financial estimates
Financial estimateRevenue estimate
Valuation estimate
BugSeq Bioinformatics leadership team
Management profileNumber of profiles
Profiles1 record
BugSeq Bioinformatics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BugSeq Bioinformatics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BugSeq Bioinformatics
What does BugSeq Bioinformatics do?
BugSeq operates a fully automated, cloud-based bioinformatics platform for microbiology labs that ingests raw sequencing data from Illumina, Nanopore, and PacBio instruments and produces actionable taxonomic classification, antimicrobial resistance prediction, outbreak surveillance, plasmid detection, quality control, subtyping, and pathogen identification reports within hours, without requiring dedicated bioinformatics infrastructure. It is sold as a tiered annual SaaS subscription (Core, Advanced, Premier) scaled by annual sample volume and regulatory feature requirements.
Is BugSeq Bioinformatics a public or private company?
BugSeq Bioinformatics is a private company. It is classified as unknown and is currently operating.
When was BugSeq Bioinformatics founded?
BugSeq Bioinformatics was founded in 2020. It employs 1 to 10 people.
Where is BugSeq Bioinformatics based?
BugSeq Bioinformatics is headquartered in Vancouver, Canada, in the North America region.
How does BugSeq Bioinformatics make money?
One revenue line is on record: subscription-based SaaS Platform.
Who are BugSeq Bioinformatics's main competitors?
Chan Zuckerberg Biohub (IDseq) is listed as an emerging player. Broad incumbents are bioMérieux, Illumina and QIAGEN. Others are Ginkgo Bioworks and DNAnexus. Direct peers are One Codex, Karius, CosmosID and Oxford Nanopore Technologies.
Does BugSeq Bioinformatics have an API?
Yes. BugSeq offers API integration support for Premier plan customers (up to 7000 samples per-year). Documentation is available at https://docs.bugseq.com. Additional details on API availability, endpoints, authentication methods, and rate limits are not publicly specified on the website. Developer documentation is at docs.bugseq.com.